FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022087368> ?p ?o ?g. }

• W2022087368 endingPage "1377" @default.
• W2022087368 startingPage "1377" @default.
• W2022087368 abstract "Thrombophilia and retinal vascular occlusion Charles J Glueck,1 Robert K Hutchins,2,3 Joel Jurantee,1 Zia Khan,1 Ping Wang11Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA; 2Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 3Cincinnati Eye Institute, Cincinnati, OH, USAPurpose: The purpose of this research was to assess associations of thrombophilia with central retinal vein occlusion (CRVO), central retinal artery occlusion (CRAO), and amaurosis fugax (AF); to evaluate outcomes of normalizing high homocysteine; and to study CRVO, CRAO, and AF developing in estrogens/estrogen agonists in women subsequently shown to have thrombophilia.Methods: Measures of thrombophilia–hypofibrinolysis were obtained in 132 CRVO cases, 15 CRAO cases, and 17 AF cases. Cases were compared to 105 healthy control subjects who did not differ by race or sex and were free of any ophthalmologic disorders. All cardiovascular disease (CVD) risk factors were compared to healthy general populations.Main outcome measures: The main outcome measure of this study was thrombophilia.Results: CRVO cases were more likely than controls to have high homocysteine (odds ratio [OR] 8.64, 95% confidence intervals [CI]: 1.96–38), high anticardiolipin immunoglobulin M (IgM; OR 6.26, 95% CI: 1.4–28.2), and high Factor VIII (OR 2.47, 95% CI: 1.31–7.9). CRAO-AF cases were more likely than controls to have high homocysteine (OR 14, 95% CI: 2.7–71.6) or the lupus anticoagulant (OR 4.1, 95% CI: 1.3–13.2). In four of 77 women with CRVO (two found to have high homocysteine, two with inherited high Factor XI), CRVO occurred after starting estrogen–progestins, estrogen–testosterone, or estrogen agonists. In one of eight women with CRAO found to have high anticardiolipin antibody IgG, CRAO occurred after starting conjugated estrogens, and AF occurred after starting conjugated estrogens in one of eleven women with AF (inherited protein S deficiency). Therapy for medians of 21 months (CRVO) and 6 months (CRAO-AF) was 5 mg folic acid, 100 mg B6, and 2000 mcg/day B12 normalized homocysteine in 13 of 16 (81%) CRVO cases and all five CRAO-AF cases with pretreatment hyperhomocysteinemia. The CRVO cases had an excess of hypertension; CRAO-AF cases had an excess of type 2 diabetes and hypertension.Conclusion: Treatable thrombophilia, hyperhomocysteinemia in particular, is more common in RVO cases than in normal controls. RVO occurs after estrogens or estrogen agonists were administered in women subsequently shown to have thrombophilia.Keywords: central retinal vein occlusion, central retinal artery occlusion, amaurosis fugax, retinal vascular occlusion, thrombophilia, estrogen, estrogen agonist" @default.
• W2022087368 created "2016-06-24" @default.
• W2022087368 creator A5013736647 @default.
• W2022087368 creator A5047679308 @default.
• W2022087368 creator A5073317941 @default.
• W2022087368 creator A5079058910 @default.
• W2022087368 creator A5089152025 @default.
• W2022087368 date "2012-08-01" @default.
• W2022087368 modified "2023-09-30" @default.
• W2022087368 title "Thrombophilia and retinal vascular occlusion" @default.
• W2022087368 cites W1511769072 @default.
• W2022087368 cites W1827794 @default.
• W2022087368 cites W1879324725 @default.
• W2022087368 cites W1973651079 @default.
• W2022087368 cites W1975830961 @default.
• W2022087368 cites W1976166811 @default.
• W2022087368 cites W1981040811 @default.
• W2022087368 cites W1986188020 @default.
• W2022087368 cites W1989270877 @default.
• W2022087368 cites W1991269015 @default.
• W2022087368 cites W1992863265 @default.
• W2022087368 cites W1994391885 @default.
• W2022087368 cites W1996016570 @default.
• W2022087368 cites W1999381981 @default.
• W2022087368 cites W2005254559 @default.
• W2022087368 cites W2006230254 @default.
• W2022087368 cites W2015521231 @default.
• W2022087368 cites W2019723755 @default.
• W2022087368 cites W2019849071 @default.
• W2022087368 cites W2022126133 @default.
• W2022087368 cites W2024314380 @default.
• W2022087368 cites W2031126430 @default.
• W2022087368 cites W2031211886 @default.
• W2022087368 cites W2036907757 @default.
• W2022087368 cites W2043004283 @default.
• W2022087368 cites W2050576350 @default.
• W2022087368 cites W2052517626 @default.
• W2022087368 cites W2054418724 @default.
• W2022087368 cites W2058543893 @default.
• W2022087368 cites W2061023003 @default.
• W2022087368 cites W2061065214 @default.
• W2022087368 cites W2062789918 @default.
• W2022087368 cites W2070817937 @default.
• W2022087368 cites W2072090277 @default.
• W2022087368 cites W2090217986 @default.
• W2022087368 cites W2091538049 @default.
• W2022087368 cites W2091790488 @default.
• W2022087368 cites W2092842782 @default.
• W2022087368 cites W2109122406 @default.
• W2022087368 cites W2109221473 @default.
• W2022087368 cites W2117259283 @default.
• W2022087368 cites W2119633014 @default.
• W2022087368 cites W2119949902 @default.
• W2022087368 cites W2127987789 @default.
• W2022087368 cites W2137724271 @default.
• W2022087368 cites W2139012224 @default.
• W2022087368 cites W2140937253 @default.
• W2022087368 cites W2142358218 @default.
• W2022087368 cites W2144514501 @default.
• W2022087368 cites W2158823864 @default.
• W2022087368 cites W2166278013 @default.
• W2022087368 cites W2170951003 @default.
• W2022087368 cites W2194762941 @default.
• W2022087368 cites W2212757632 @default.
• W2022087368 cites W2223268602 @default.
• W2022087368 cites W2266879013 @default.
• W2022087368 cites W2269595614 @default.
• W2022087368 cites W2275724418 @default.
• W2022087368 cites W2289713678 @default.
• W2022087368 cites W2289941100 @default.
• W2022087368 cites W2325428388 @default.
• W2022087368 cites W2401868989 @default.
• W2022087368 cites W2413005045 @default.
• W2022087368 cites W79828104 @default.
• W2022087368 cites W3024189182 @default.
• W2022087368 doi "https://doi.org/10.2147/opth.s34627" @default.
• W2022087368 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3437951" @default.
• W2022087368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22969282" @default.
• W2022087368 hasPublicationYear "2012" @default.
• W2022087368 type Work @default.
• W2022087368 sameAs 2022087368 @default.
• W2022087368 citedByCount "36" @default.
• W2022087368 countsByYear W20220873682013 @default.
• W2022087368 countsByYear W20220873682014 @default.
• W2022087368 countsByYear W20220873682015 @default.
• W2022087368 countsByYear W20220873682016 @default.
• W2022087368 countsByYear W20220873682017 @default.
• W2022087368 countsByYear W20220873682018 @default.
• W2022087368 countsByYear W20220873682019 @default.
• W2022087368 countsByYear W20220873682020 @default.
• W2022087368 countsByYear W20220873682021 @default.
• W2022087368 countsByYear W20220873682022 @default.
• W2022087368 countsByYear W20220873682023 @default.
• W2022087368 crossrefType "journal-article" @default.
• W2022087368 hasAuthorship W2022087368A5013736647 @default.
• W2022087368 hasAuthorship W2022087368A5047679308 @default.
• W2022087368 hasAuthorship W2022087368A5073317941 @default.
• W2022087368 hasAuthorship W2022087368A5079058910 @default.

• next